Overview
I am a clinically-oriented diagnostic physician with clinical expertise in the diagnosis of hematologic cancers including tumors of the bone marrow, lymphoid tissue, spleen and pre-malignant hematologic conditions. Another area of interest is blood cancer classification with molecular and genetic profiling. In the pathology translational program, we focus on molecular mechanisms of tumor progression, cell-of-origin, biomarkers, and novel therapeutic strategies in lymphoma, myeloma and leukemia. In addition to patient care and translational research, medical education and communication are also part of focus. I provide persistent support for the physician-scientist program and Blood Cancer Pathology program in the department and cancer center. Many residents, fellows, graduates and postdocs have worked and been trained in our program. We perform comprehensive clinical and research functions that include bone marrow, lymphoma pathology, clinical flow cytometry, cytogenetics, molecular diagnostics and outside services.
I am currently the director of hematopathology division and Vice Chair of Research in the Department that provides diagnostic services and relevant specialized testing for patients with various types of acute and chronic leukemia, lymphoma and benign hematologic disorders. I am specialized in the diagnosis of hematological disorders, including acute and chronic leukemias, myelodysplastic syndromes, myeloproliferative neoplasms, B and T-cell lymphomas, Hodgkin lymphoma, cutaneous and orbital lymphomas and benign bone marrow and lymph node disorders.
Our clinical and research collaborative groups have been supported by various funding resources since 2006 and have presented original peer-reviewed articles and review articles, some of which are in high-impact journals (Nature Clin Onc Rev, JCO, JAMA, Lancet, Blood, JHO, Leukemia and Clinical Cancer Research). The contributions to the hematology field include the development of novel diagnostic algorithms, molecular and genetic biomarkers for classification of blood cancer, lymphoid neoplasms and lymphoid diseases.
Office Hours
Division of Hematopathology and Department of Pathology, Duke University School of Medicine, Duke University Medical Center and Cancer Institute, 40 Duke Medicine Circle, Room 265M, Box 3712, Duke South, Green Zone, Durham, NC 27710. Office Phone: 1-919-668-7568
Current Duke Appointments & Affiliations
Recent Scholarly Works
Loss of systemic anti-viral immunity and LMP1-driven suppressive myeloid tumour niches converge to shape the immunobiology of Epstein-Barr virus-positive diffuse large B-cell lymphoma.
Journal article Leukemia · August 2026 Epstein-Barr virus (EBV)-positive diffuse large B-cell lymphoma (EBV⁺DLBCL) is an aggressive lymphoma with poor outcomes and an incompletely understood pathogenesis, frequently attributed to immunosenescence. However, its occurrence across all age groups s ... Full text Link to item CiteApplication of Hi-C sequencing to detect oncogene rearrangements for diagnosis and treatment of large B-cell lymphoma.
Journal article Blood Adv · June 16, 2026 Diffuse large B-cell lymphoma (DLBCL), the most common type of lymphoma, arises from various pathogenic mechanisms including gene translocations and fusions. Detection of gene rearrangements using fluorescence in situ hybridization (FISH) is a standard pra ... Full text Link to item CiteFrom Data to Decisions: Machine Learning Transforms Infant Acute Myeloid Leukemia Prognosis
Journal article Medcomm Future Medicine · June 1, 2026 Full text CiteRecent Grants
PD-L1 Modifications in Cancer Diagnosis and Treatment
ResearchPrincipal Investigator · Awarded by Baylor College of Medicine · 2025 - 2030Cancer Prevention-Interception against MGUS Progression (Admin Core)
ResearchPrincipal Investigator · Awarded by Baylor College of Medicine · 2023 - 2027Spatially resolved, single cell biomarkers of B cell lymphoma
ResearchPrincipal Investigator · Awarded by Cedars Sinai Medical Center · 2022 - 2027View All Grants